Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 2/20 | 0.33 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26322346 | 0.83 | TSHR (0.32) | TSHRUSP2 | |
| SCHEMBL26322459 | 0.78 | — | — | |
| SCHEMBL12122789 | 0.74 | TSHR (0.34) | GRIK1GRIK2BLMMEN1TSHR | |
| SCHEMBL26323184 | 0.72 | CTSK (0.43) | — | |
| SCHEMBL26322350 | 0.72 | CTSK (0.43) | — | |
| SCHEMBL26324362 | 0.69 | GRIK1 (0.33) | GRIK1GRIK2SLC6A2SLC6A4BLM | |
| SCHEMBL30241893 | 0.66 | TSHR (0.40) | GRIK1GRIK2BLMMEN1TSHR | |
| SCHEMBL2463676 | 0.65 | GRIK1 (0.38) | GRIK1GRIK2MEN1TSHRKMT2A | |
| SCHEMBL8377632 | 0.64 | — | — | |
| SCHEMBL964294 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230278955-A1 | VITAMIN D3 DERIVATIVES AND PHARMACEUTICAL USE THEREOF | UNIV KYOTO (JP) | 2023-09-07 | — | — | US | disclosed |
| US-20230278955-A1 | VITAMIN D3 DERIVATIVES AND PHARMACEUTICAL USE THEREOF | UNIV KYOTO (JP) | 2023-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230278955-A1 | VITAMIN D3 DERIVATIVES AND PHARMACEUTICAL USE THEREOF | VDR, CYP24A1, CYP2R1 | GRIK1 4788/4885GRIK2 4812/4885SLC6A2 3395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.